Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
AssigneeBASF SE
InventorsSvein Olaf Hustvedt, Preben Houlberg Olesen, Annette Müllertz
Life of this patent
Estimating the term…
Abstract
Compositions comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid, an ester derivative, or a pharmaceutically acceptable salt thereof; a triglyceride; and a surfactant, as well as methods for their use. The present disclosure further relates to self-emulsifying drug delivery systems, such as SEDDS, SMEDDS, or SNEDDS comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid.
Claims20
A method for the treatment of a disease or condition chosen from:
- a dyslipidemic condition;
- and/or
- elevated triglyceride levels, non-HDL cholesterol levels, LDL cholesterol levels, and/or VLDL cholesterol levels;
- in a subject in need thereof, comprising administering to the subject a pharmaceutically active amount of a composition comprising from 5% to 60% by weight of the total composition of 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid, and ester derivative, or a pharmaceutically acceptable salt thereof;
- from 15% to 60% by weight of the total composition of a medium-chain triglyceride (MCT) oil;
- and
- from 10% to 60% by weight of the total composition of a nonionic surfactant.
A method for the treatment of a disease or condition chosen from an inflammatory disease or condition and/or atherosclerosis in a subject in need thereof, comprising administering to the subject a pharmaceutically active amount of a composition comprising from 5% to 60% by weight of the total composition of 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid, and ester derivative, or a pharmaceutically acceptable salt thereof;
- from 15% to 60% by weight of the total composition of a medium-chain triglyceride (MCT) oil;
- and
- from 10% to 60% by weight of the total composition of a nonionic surfactant.
A method for the treatment of a disease or condition chosen from peripheral insulin resistance, a diabetic condition, and/or type 2 diabetes in a subject in need thereof, comprising administering to the subject a pharmaceutically active amount of a composition comprising from 5% to 60% by weight of the total composition of 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid, and ester derivative, or a pharmaceutically acceptable salt thereof;
- from 15% to 60% by weight of the total composition of a medium-chain triglyceride (MCT) oil;
- and
- from 10% to 60% by weight of the total composition of a nonionic surfactant.
Dependencies are inferred from the claim text.